A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity

Vaccine

Volumn 28, Issue 12, 2010, Pages 2428-2435

  Smallshaw, Joan E ^a   Vitetta, Ellen S ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Lyophilization; Ricin; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; RECOMBINANT VACCINE; RICIN A; RIVAX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; FEMALE; FREEZE DRYING; FREEZING; IMMUNOGENICITY; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; ROOM TEMPERATURE; STORAGE TEMPERATURE;

ANIMALS; ANTITOXINS; DRUG STABILITY; DRUG STORAGE; FEMALE; FREEZE DRYING; INJECTIONS, INTRAMUSCULAR; MICE; POISONING; PROTEIN SUBUNITS; RICIN; SURVIVAL ANALYSIS; VACCINES;

EID: 77249085103     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.12.081     Document Type: Article

References (30)

1. Doan L.G. Ricin: mechanism of toxicity, clinical manifestations, and vaccine development. A review. J Toxicol: Clin Toxicol 42 2 (2004) 201-208
2. Audi J., Belson M., Patel M., Schier J., and Osterloh J. Ricin poisoning: a comprehensive review. JAMA 294 18 (2005) 2342-2351
3. Franz D.R., and Jaax N.K. Ricin toxin. In: Zajtchuk R., and Bellamy R.F. (Eds). Textbook of military medicine (1997), Office of the Surgeon General at TMM Publications, Borden Inst., Walter Reed Army Medical Center, Washington, DC 631-642
4. Smallshaw J.E., Richardson J.A., and Vitetta E.S. RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol. Vaccine 25 42 (2007) 7459-7469
5. Hewetson J.F., Rivera V.R., Creasia D.A., Lemley P.V., Rippy M.K., and Poli M.A. Protection of mice from inhaled ricin by vaccination with ricin or by passive treatment with heterologous antibody. Vaccine 11 7 (1993) 743-746
6. Lemley P.V., Amanatides P., and Wright D.C. Identification and characterization of a monoclonal antibody that neutralizes ricin toxicity in vitro and in vivo. Hybridoma 13 5 (1994) 417-421
7. Griffiths G.D., Bailey S.C., Hambrook J.L., and Keyte M.P. Local and systemic responses against ricin toxin promoted by toxoid or peptide vaccines alone or in liposomal formulations. Vaccine 16 5 (1998) 530-535
8. Poli M.A., Rivera V.R., Pitt M.L., and Vogel P. Aerosolized specific antibody protects mice from lung injury associated with aerosolized ricin exposure. Toxicon 34 9 (1996) 1037-1044
9. Foxwell B.M., Detre S.I., Donovan T.A., and Thorpe P.E. The use of anti-ricin antibodies to protect mice intoxicated with ricin. Toxicology 34 1 (1985) 79-88
10. Smallshaw J.E., Firan A., Fulmer J.R., Ruback S.L., Ghetie V., and Vitetta E.S. A novel recombinant vaccine which protects mice against ricin intoxication. Vaccine 20 27-28 (2002) 3422-3427
11. Smallshaw J.E., Richardson J.A., Pincus S., Schindler J., and Vitetta E.S. Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin. Vaccine 23 39 (2005) 4775-4784
12. Vitetta E.S., Smallshaw J.E., Coleman E., Jafri H., Foster C., Munford R., et al. A pilot clinical trial of a recombinant ricin vaccine in normal humans. Proc Natl Acad Sci USA 103 7 (2006) 2268-2273
13. O'Hare M., Brown A.N., Hussain K., Gebhardt A., Watson G., Roberts L.M., et al. Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a proteolytically-cleavable spacer sequence. FEBS Lett 273 1-2 (1990) 200-204
14. Simpson J.C., Lord J.M., and Roberts L.M. Point mutations in the hydrophobic C-terminal region of ricin A chain indicate that Pro250 plays a key role in membrane translocation. Eur J Biochem 232 (1995) 458-463
15. Sambrook J., Fritsch E.F., and Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
16. Peek L.J., Brey R.N., and Middaugh C.R. A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine. J Pharm Sci 96 1 (2007) 44-60
17. Simmons B.M., and Russell J.H. A single affinity column step method for the purification of ricin toxin from castor beans (Ricinus communis). Anal Biochem 146 1 (1985) 206-210
18. Depledge M.H. Respiration and lung function in the mouse, Mus musculus (with a note on mass exponents and respiratory variables). Respir Physiol 60 1 (1985) 83-94
19. Rios A.M., Mejias A., Chavez-Bueno S., Fonseca-Aten M., Katz K., Hatfield J., et al. Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection. Antimicrob Agents Chemother 48 8 (2004) 2897-2904
20. Hu Y., Tan S., Shao C., Jin W., Ji Q., He J., et al. Safety and immunogenecity of lyophilized live attenuated hepatitis A vaccine in non-human primate model. Chin Med J 113 4 (2000) 332-335
21. Maa Y.F., Ameri M., Shu C., Payne L.G., and Chen D. Influenza vaccine powder formulation development: spray freeze-drying and stability evaluation. J Pharm Sci 93 7 (2004) 1912-1923
22. Zhai S., Hansen R.K., Taylor R., Skepper J.N., Sanches R., and Slater N.K. Effect of freezing rates and excipients on the infectivity of a live viral vaccine during lyophilization. Biotechnology 20 4 (2004) 1113-1120
23. Monath T.P. Stability of yellow fever vaccine. Dev Biol Stand 87 1 (1996) 219-225
24. Diminksy D., Moav N., Gorecki M., and Barenholz Y. Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. Vaccine 18 1-2 (1999) 3-17
25. Paoletti L.C. Potency of clinical group B streptococcal conjugate vaccines. Vaccine 19 15-16 (2001) 2118-2126
26. Maa Y.F., Zhao L., Payne L.G., and Chen D. Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application. J Pharm Sci 92 2 (2003) 319-332
27. Chen D., Tyagi A., Carpenter J., Perkins S., Sylvester D., Guy M., et al. Characterization of the freeze sensitivity of a hepatitis B vaccine. Hum Vaccines 5 1 (2009) 26-32
28. Clausi A., Cummiskey J., Merkley S., Carpenter J.F., Braun L.J., and Randolph T.W. Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine. J Pharm Sci 97 12 (2008) 5252-5262
29. Amorij J.P., Huckriede A., Wilschut J., Frijlink H.W., and Hinrichs W.L. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res 25 6 (2008) 1256-1273
30. Braun L.J., Tyagi A., Perkins S., Carpenter J., Sylvester D., Guy M., et al. Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants. Vaccine 27 1 (2009) 72-79